Facebook
Twitter
LinkedIn
ForwardSelf-Directed Review in GCRA - Bundle 8 | Tumor/Germline Testing - Understanding and Interpreting Clonal Hematopoiesis
Identifying hereditary cancer predisposition through genetic cancer risk assessment (GCRA) allows for intensified measures to prevent cancers or detect them at an earlier, more treatable stage. Once delivered primarily through academic health centers, the demand for GCRA services in the community setting is steadily increasing. There is a surge in demand for GCRA services across the nation, but too few clinicians with adequate training to provide GCRA services.
The increasing demand for GCRA services has been fueled by the rapid evolution of genetic information and direct-to-consumer marketing by commercial genetic testing vendors.
Target Audience
Physicians, Physician Assistants, Genetic Counselors, Master's or PhD in Genetics or Advanced Practice Nurses, and Geneticists.
Learning Objectives
- Describe the differences between a high, moderate, and low penetrance cancer susceptibility gene.
- Counsel a patient about moderate and low penetrance cancer susceptibility genes found on routine clinical testing.
- Identify that moderate and low penetrance cancer susceptibility genes may not track with the family history of cancer.
- Recognize that cancer susceptibility genes on clinical panels are not always actionable.
- Compare the benefits and challenges of somatic panel, germline panel and paired somatic/germline sequencing.
- Identify issues related to incidental findings in cancer sequencing.
- Discriminate strategies used to interpret genomic data.
- Examine ways that genomic data are changing cancer treatment paradigms.
- Discuss some of the patient, provider, and system-level challenges to genomic test integration.
- Review the various possible mechanisms of both germline and somatic mosaicism.
- Identify the various mechanisms that can be associated with an altered allelic fraction in a germline genetic test.
- Discuss approaches to interpreting, further evaluating, and following up on genetic test results reporting low allelic fractions.
- Discuss possible barriers and biases which may impact patient care (i.e., race, ethnicity, language, gender identity/orientation, age, socioeconomic status, attitudes, feelings, or other characteristics).
This activity has been planned and implemented in strict compliance with the accreditation requirements, standards, and policies of the ACCME. City of Hope takes responsibility for the content, quality and scientific integrity of this CME activity.
As an accredited CME provider City of Hope requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 24 months. Faculty presenters who are in a position to control the content of an educational activity must identify any real or apparent conflict(s) of interest by disclosing to the Department of CME all relevant financial relationships with any ineligible company, which is defined as any entity whose primary business is to produce, market , sell, re-sell or distribute healthcare products used by or on patients. To comply with more intense scrutiny by accreditation agencies, content whose faculty has disclosed any relevant financial relationships with an ineligible company, have been peer reviewed prior to presenting and any potential conflicts relative to the previous disclosure have been resolved.
Presenters/Planners: Listing of Faculty and respective Disclosures
The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.
CME Committee/Reviewer Nothing to Disclose: Daneng Li, MD
City of Hope further encourages faculty/ authors to identify investigational products or off-label uses of products regulated by the U.S. Food and Drug Administration, at first mention and where appropriate in the content.
The information and opinions presented in this activity do not constitute medical or legal advice. Health care providers must exercise their own professional judgment in their clinical practice, and when confronted with the issues discussed herein, should not substitute this curriculum for the advice of legal counsel or application of sound ethical principles.
This activity has received no commercial support.
ACCREDITATION STATEMENT: City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION: City of Hope designates this enduring activity for a maximum of 3.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The following credit type(s) are being offered for this course:
• AMA PRA Category 1 Credit™ 3.5
The following may apply AMA PRA Category 1 Credit™ for license renewal:
Registered Nurses: Nurses may report up to 3.5 credit hours toward the continuing education requirements for license renewal by their state Board of Registered Nurses (BRN). AMA PRA Category 1 Credit™ may be noted on the license renewal application in lieu of a BRN provider number.
Physician Assistants: The National Commission on Certification of Physicians Assistants states that AMA PRA Category 1 Credit™ accredited courses are acceptable for CME requirements for recertification.
Available Credit
- 3.50 AMA PRA Category 1 Credit™City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
City of Hope designates this Self-Directed Review in GCRA - Bundle 8 | Tumor/Germline Testing - Understanding and Interpreting Clonal Hematopoiesis for a maximum of 3.50 AMA PRA Category 1 Credit™ requirements. Physicians should claim only the credit commensurate with the extent of their participation in the activity. - 3.50 Attendance